GLOBAL - Shareholder value in pharmaceuticals is under threat if companies do not confront the health crisis in developing nations. Some 11 leading institutional investors across Europe, representing about £600bn in assets, have issued a statement to major pharmaceutical companies on how they should respond to global crises, such as Aids/HIV. They warn the industry that failure to defend drug patents may result in damage to its reputation, as well as profitability - similar to the tobacco industry.
Investors, including ISIS Asset Management, the Universities Superannuation Scheme, Legal & General and Schroder in the UK and PGGM, the second largest Dutch pension fund by assets, have signed the...
To continue reading this article...
Join Professional Pensions
- Unlimited access to real-time news, analysis and opinion from the industry
- Receive our in-depth monthly magazine in either print or digital format
- Access our Sustainable Investment Hub covering news and opinion from thought leaders in the ESG space
- Receive important and breaking news stories selected by the Editors in our daily newsletter
- Hear from industry experts and other forward-thinking leaders
- Receive a monthly members-only newsletter with exclusive opinion pieces from leading industry experts and a feature from the magazine in advance of its release date